Xeris Biopharma Holdings, Inc. (XERS)

Market Cap	858.99M
Revenue (ttm)	203.07M
Net Income (ttm)	-54.84M
Shares Out	153.94M
EPS (ttm)	-0.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,978,506
Open	5.63
Previous Close	5.63
Day's Range	5.51 - 5.70
52-Week Range	1.69 - 6.07
Beta	1.21
Analysts	Strong Buy
Price Target	5.92 (+6.09%)
Earnings Date	Mar 6, 2025

About XERS

Xeris Biopharma Holdings, Inc., engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also de...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 21, 2018
• Employees: 394
• Stock Exchange: NASDAQ
• Ticker Symbol: XERS
• Website: https://www.xerispharma.com

Financial Performance

In 2024, Xeris Biopharma Holdings's revenue was $203.07 million, an increase of 23.89% compared to the previous year's $163.91 million. Losses were -$54.84 million, -11.92% less than in 2023.

Analyst Forecast

According to 6 analysts, the average rating for XERS stock is "Strong Buy." The 12-month stock price forecast is $5.92, which is an increase of 6.09% from the latest price.

Price Target

$5.92

(6.09% upside)

Analyst Consensus: Strong Buy